Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma.
Cancer. 2015.
PMID: 25186283
Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2021 | 1 |
| 2024 | 0 |
Search Results
3 results
Results by year
Citations
1
article
found by citation matching
Search results
Filters applied: . Clear all
Page 1
Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma.
Haddad AQ, Kapur P, Singla N, Raman JD, Then MT, Nuhn P, Buchner A, Bastian P, Seitz C, Shariat SF, Bensalah K, Rioux-Leclercq N, Sagalowsky A, Lotan Y, Margulis V.
Haddad AQ, et al.
Cancer. 2015 Jan 1;121(1):43-50. doi: 10.1002/cncr.28976. Epub 2014 Sep 3.
Cancer. 2015.
PMID: 25186283
Free article.
BACKGROUND: This was an external validation of the prognostic benefit of mammalian target of rapamycin (mTOR) marker panel in patients with clear cell renal cell carcinoma (ccRCC). ...A biomark …
BACKGROUND: This was an external validation of the prognostic benefit of mammalian target of rapamycin (m …
Item in Clipboard
Precision medicine for metastatic renal cell carcinoma.
Sonpavde G, Choueiri TK.
Sonpavde G, et al.
Urol Oncol. 2014 Jan;32(1):5-15. doi: 10.1016/j.urolonc.2013.07.010. Epub 2013 Nov 13.
Urol Oncol. 2014.
PMID: 24239472
Review.
OBJECTIVES: This review provides a broad overview of emerging data that provide hope that rational precision medicine for metastatic renal cell carcinoma (RCC) may be possible. METHODS: PubMed and major conferences were searched for studies reporting potentia …
OBJECTIVES: This review provides a broad overview of emerging data that provide hope that rational precision medicine for metastatic rena …
Item in Clipboard
The Potential and Limitations of Precision Oncology: Lessons Learned from Whole-Exome Sequencing in an Exceptional Response to Everolimus in Advanced Renal Cell Carcinoma.
Pilling A, Wee C, Bar-Meir E, Dyson G, Hwang O, Gupta N, Chitale D, Hwang C.
Pilling A, et al.
Case Rep Oncol. 2021 Aug 16;14(2):1194-1200. doi: 10.1159/000516277. eCollection 2021 May-Aug.
Case Rep Oncol. 2021.
PMID: 34703436
Free PMC article.
We identified an exceptional responder to everolimus, an oral inhibitor of the mammalian target of rapamycin (mTOR) pathway, in a patient with advanced renal cell carcinoma. ...Further research to discover and validate …
We identified an exceptional responder to everolimus, an oral inhibitor of the mammalian target of rapamycin (mT …
Item in Clipboard
Cite
Cite